{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:44:13Z","timestamp":1787755453007,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"USDA-ARS CRIS","award":["# 2090\u201332000-044-000-D"],"award-info":[{"award-number":["# 2090\u201332000-044-000-D"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Equine piroplasmosis (EP) is a tick-borne disease of equids caused by the intraerythrocytic apicomplexan parasites\n                      <jats:italic>Theileria equi<\/jats:italic>\n                      ,\n                      <jats:italic>Babesia caballi<\/jats:italic>\n                      and the recently identified\n                      <jats:italic>Theileria haneyi<\/jats:italic>\n                      . Acute cases can be severe, with anemia, jaundice, abortion or sudden death. Survivors remain lifelong carriers, serving as reservoirs for tick-borne and iatrogenic transmission. No vaccines are currently available, and control strategies rely heavily on accurate diagnostics and chemotherapeutic intervention. Imidocarb dipropionate (ID) is the current standard of care for both acute treatment and radical cure. However, growing concerns regarding ID-resistant parasite strains and its associated toxicity have highlighted the urgent need for novel, safer and more effective antiparasitic agents. Here, we assessed the in vitro efficacy of tafenoquine succinate (TFQ), a synthetic 8-aminoquinoline with broad antiparasitic activity, against\n                      <jats:italic>T. equi<\/jats:italic>\n                      and\n                      <jats:italic>B. caballi<\/jats:italic>\n                      as a potential treatment for equine piroplasmosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The effect of TFQ on\n                      <jats:italic>T. equi<\/jats:italic>\n                      and\n                      <jats:italic>B. caballi<\/jats:italic>\n                      was evaluated in vitro in parasite cultures. The percentage of parasitized erythrocytes was measured by flow cytometry, and the effect of TFQ on parasite growth was compared to that of ID. TFQ toxicity on horse peripheral blood mononuclear cells (PBMCs) was assessed via a colorimetric metabolic assay.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      TFQ reduced\n                      <jats:italic>T. equi<\/jats:italic>\n                      parasitemia in a dose-dependent manner, matching ID efficacy at 72\u00a0h. For\n                      <jats:italic>B. caballi<\/jats:italic>\n                      , TFQ had no effect at 5\u201310\u00a0\u00b5M but inhibited growth at 15\u00a0\u00b5M, similar to the  results obtained with ID. TFQ exhibited approximately threefold greater potency against\n                      <jats:italic>T. equi<\/jats:italic>\n                      [half-maximal inhibitory concentration [IC\n                      <jats:sub>50<\/jats:sub>\n                      ] 5.90\u00a0\u03bcM, 95% confidence interval (CI) 4.99\u20135.96; 99% inhibitory concentration (IC\n                      <jats:sub>99<\/jats:sub>\n                      ) 60.74\u00a0\u03bcM, 95% CI 37.41\u2013113.3] compared to\n                      <jats:italic>B. caballi<\/jats:italic>\n                      [IC\n                      <jats:sub>50<\/jats:sub>\n                      14.5\u00a0\u03bcM, 95% CI 13.81\u201315.23; IC\n                      <jats:sub>99<\/jats:sub>\n                      20.44\u00a0\u03bcM, 95% CI 17.77\u201328.84]. The narrower confidence intervals for\n                      <jats:italic>T. equi<\/jats:italic>\n                      suggest a more consistent antiparasitic response across replicates. Cytotoxicity assays showed no toxic effects on equine PBMCs at 2.5\u20135\u00a0\u03bcM (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05), while concentrations\u2009\u2265\u200910\u00a0\u03bcM indicated potential toxicity. These findings suggest that TFQ selectively targets parasites over host cells, supporting its therapeutic potential.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      TFQ significantly inhibited\n                      <jats:italic>T. equi<\/jats:italic>\n                      and\n                      <jats:italic>B. caballi<\/jats:italic>\n                      growth at doses tolerated by equine PBMCs, supporting its potential as an alternative treatment for EP and warranting further in vivo study.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13071-026-07262-y","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:37:38Z","timestamp":1769513858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tafenoquine succinate inhibits the growth of the equine piroplasmosis hemoparasites Theileria equi and Babesia caballi"],"prefix":"10.1186","volume":"19","author":[{"given":"Natalia N.","family":"Cardillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas F.","family":"Villarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowell S.","family":"Kappmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chungwon J.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginaldo G.","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"7262_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2024.1459989","author":"FJ Mendoza","year":"2024","unstructured":"Mendoza FJ, P\u00e9rez-\u00c9cija A, Kappmeyer LS, Suarez CE, Bastos RG. New insights in the diagnosis and treatment of equine piroplasmosis: pitfalls, idiosyncrasies, and myths. Front Vet Sci. 2024. https:\/\/doi.org\/10.3389\/fvets.2024.1459989.","journal-title":"Front Vet Sci"},{"key":"7262_CR2","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/jvim.12168","volume":"27","author":"LN Wise","year":"2013","unstructured":"Wise LN, Kappmeyer LS, Mealey RH, Knowles DP. Review of equine piroplasmosis. J Vet Intern Med. 2013;27:1334\u201346. https:\/\/doi.org\/10.1111\/jvim.12168.","journal-title":"J Vet Intern Med"},{"key":"7262_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ttbdis.2022.101904","volume":"13","author":"MA Rizk","year":"2022","unstructured":"Rizk MA, El-Sayed SAE-S, Eltaysh R, Igarashi I. MMV020275 and MMV020490, promising compounds from malaria box for the treatment of equine piroplasmosis. Ticks Tick-Borne Dis. 2022;13:101904. https:\/\/doi.org\/10.1016\/j.ttbdis.2022.101904.","journal-title":"Ticks Tick-Borne Dis"},{"key":"7262_CR4","doi-asserted-by":"publisher","unstructured":"Silva MG, Bastos RG, Stone Doggett J, Riscoe MK, Pou S, Winter R, et al. Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis B. bigemina, B. caballi and Theileria equi. Parasit Vectors. 2020;13:606. https:\/\/doi.org\/10.1186\/s13071-020-04487-3.","DOI":"10.1186\/s13071-020-04487-3"},{"key":"7262_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16101736","volume":"16","author":"TE Onyiche","year":"2019","unstructured":"Onyiche TE, Suganuma K, Igarashi I, Yokoyama N, Xuan X, Thekisoe O. A review on equine piroplasmosis: epidemiology, vector ecology, risk factors, host immunity, diagnosis and control. Int J Environ Res Public Health. 2019;16:1736. https:\/\/doi.org\/10.3390\/ijerph16101736.","journal-title":"Int J Environ Res Public Health"},{"key":"7262_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.vetpar.2016.07.008","volume":"226","author":"C Sant","year":"2016","unstructured":"Sant C, d\u2019Abadie R, Pargass I, Basu AK, Asgarali Z, Charles RA, et al. Prospective study investigating transplacental transmission of equine piroplasmosis in thoroughbred foals in Trinidad. Vet Parasitol. 2016;226:132\u20137. https:\/\/doi.org\/10.1016\/j.vetpar.2016.07.008.","journal-title":"Vet Parasitol"},{"key":"7262_CR7","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-41235\/v1","author":"A Suthar","year":"2021","unstructured":"Suthar A, Maji C, Gopalkrishnan A, Raval SH, Kumar R, Kumar S. Anti-piroplasmic activity of novobiocin as heat shock protein 90 inhibitor against in vitro cultured Theileria equi and Babesia caballi parasites. Ticks Tick-Borne Dis. 2021. https:\/\/doi.org\/10.21203\/rs.3.rs-41235\/v1.","journal-title":"Ticks Tick-Borne Dis"},{"key":"7262_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13071-014-0611-6","volume":"8","author":"SA Hines","year":"2015","unstructured":"Hines SA, Ramsay JD, Kappmeyer LS, Lau AOT, Ojo KK, Van Voorhis WC, et al. Theileria equi isolates vary in susceptibility to imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitor. Parasit Vectors. 2015;8:1\u201311. https:\/\/doi.org\/10.1186\/s13071-014-0611-6.","journal-title":"Parasit Vectors"},{"key":"7262_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pathogens9121035","volume":"9","author":"K Sears","year":"2020","unstructured":"Sears K, Knowles D, Dinkel K, Mshelia PW, Onzere C, Silva M, et al. Imidocarb dipropionate lacks efficacy against Theileria haneyi and fails to consistently clear Theileria equi in horses co-infected with T. haneyi. Pathogens. 2020;9:1\u201312. https:\/\/doi.org\/10.3390\/pathogens9121035.","journal-title":"Pathogens"},{"key":"7262_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.tvjl.2012.10.025","volume":"196","author":"JF Grause","year":"2013","unstructured":"Grause JF, Ueti MW, Nelson JT, Knowles DP, Kappmeyer LS, Bunn TO. Efficacy of imidocarb dipropionate in eliminating Theileria equi from experimentally infected horses. Vet J. 2013;196:541\u20136. https:\/\/doi.org\/10.1016\/j.tvjl.2012.10.025.","journal-title":"Vet J"},{"key":"7262_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044713","volume":"7","author":"MW Ueti","year":"2012","unstructured":"Ueti MW, Mealey RH, Kappmeyer LS, White SN, Kumpula-McWhirter N, Pelzel AM, et al. Re-emergence of the apicomplexan Theileria equi in the United States: elimination of persistent infection and transmission risk. PLoS ONE. 2012;7:e44713. https:\/\/doi.org\/10.1371\/journal.pone.0044713.","journal-title":"PLoS ONE"},{"key":"7262_CR12","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.2165\/00003495-200565150-00003","volume":"65","author":"GD Shanks","year":"2005","unstructured":"Shanks GD, Edstein MD. Modern malaria chemoprophylaxis. Drugs. 2005;65:2091\u2013110. https:\/\/doi.org\/10.2165\/00003495-200565150-00003.","journal-title":"Drugs"},{"key":"7262_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/milmed\/usz304","volume":"185","author":"VE Zottig","year":"2020","unstructured":"Zottig VE, Carr KA, Clarke JG, Shmuklarsky MJ, Kreishman-Deitrick M. Army antimalarial drug development: an advanced development case study for tafenoquine. Mil Med. 2020;185:617\u201323. https:\/\/doi.org\/10.1093\/milmed\/usz304.","journal-title":"Mil Med"},{"key":"7262_CR14","doi-asserted-by":"publisher","unstructured":"Ebstie YA, Abay SM, Tadesse WT, A. Ejigu D. Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. Drug Des Dev Ther. 2016;10:2387\u201399. https:\/\/doi.org\/10.2147\/DDDT.S61443.","DOI":"10.2147\/DDDT.S61443"},{"key":"7262_CR15","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.83433","author":"JA Watson","year":"2022","unstructured":"Watson JA, Commons RJ, Tarning J, Simpson JA, Cuentas AL, Lacerda MV, et al. The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis. Elife. 2022. https:\/\/doi.org\/10.7554\/eLife.83433.","journal-title":"Elife"},{"key":"7262_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ijpara.2018.11.007","volume":"49","author":"PJ Krause","year":"2019","unstructured":"Krause PJ. Human babesiosis. Int J Parasitol. 2019;49:165\u201374. https:\/\/doi.org\/10.1016\/j.ijpara.2018.11.007.","journal-title":"Int J Parasitol"},{"key":"7262_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/infdis\/jiad315","volume":"229","author":"P Vydyam","year":"2024","unstructured":"Vydyam P, Pal AC, Renard I, Chand M, Kumari V, Gennaro JC, et al. Tafenoquine-atovaquone combination achieves radical cure and confers sterile immunity in experimental models of human babesiosis. J Infect Dis. 2024;229:161\u201372. https:\/\/doi.org\/10.1093\/infdis\/jiad315.","journal-title":"J Infect Dis"},{"key":"7262_CR18","doi-asserted-by":"publisher","first-page":"5344","DOI":"10.1128\/AAC.00790-10","volume":"54","author":"L Carvalho","year":"2010","unstructured":"Carvalho L, Luque-Ortega JR, Manzano JI, Castanys S, Rivas L, Gamarro F. Tafenoquine, an antiplasmodial 8-aminoquinoline, targets Leishmania respiratory complex iii and induces apoptosis. Antimicrob Agents Chemother. 2010;54:5344\u201351. https:\/\/doi.org\/10.1128\/AAC.00790-10.","journal-title":"Antimicrob Agents Chemother"},{"key":"7262_CR19","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s40265-018-0979-2","volume":"78","author":"JE Frampton","year":"2018","unstructured":"Frampton JE. Tafenoquine: first global approval. Drugs. 2018;78:1517\u201323. https:\/\/doi.org\/10.1007\/s40265-018-0979-2.","journal-title":"Drugs"},{"key":"7262_CR20","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1128\/AAC.43.3.598","volume":"43","author":"JL Vennerstrom","year":"1999","unstructured":"Vennerstrom JL, Nuzum EO, Miller RE, Dorn A, Gerena L, Dande PA, et al. 8-Aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit hematin polymerization. Antimicrob Agents Chemother. 1999;43:598\u2013602. https:\/\/doi.org\/10.1128\/AAC.43.3.598.","journal-title":"Antimicrob Agents Chemother"},{"key":"7262_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2147\/IDR.S151031","volume":"12","author":"AB Hounkpatin","year":"2019","unstructured":"Hounkpatin AB, Kreidenweiss A, Held J. Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data. Infect Drug Resist. 2019;12:553\u201370. https:\/\/doi.org\/10.2147\/IDR.S151031.","journal-title":"Infect Drug Resist"},{"key":"7262_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-2724-z","volume":"18","author":"EG Tse","year":"2019","unstructured":"Tse EG, Korsik M, Todd MH. The past, present and future of anti-malarial medicines. Malar J. 2019;18:93. https:\/\/doi.org\/10.1186\/s12936-019-2724-z.","journal-title":"Malar J"},{"key":"7262_CR23","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1021\/acs.biochem.9b01105","volume":"59","author":"K-Y Lu","year":"2020","unstructured":"Lu K-Y, Derbyshire ER. Tafenoquine: a step toward malaria elimination. Published as part of the Biochemistry series \u201cBiochemistry to Bedside.\u201d Biochemistry. 2020;59:911\u201320. https:\/\/doi.org\/10.1021\/acs.biochem.9b01105.","journal-title":"Biochemistry"},{"key":"7262_CR24","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1128\/AAC.01183-06","volume":"51","author":"BG Charles","year":"2007","unstructured":"Charles BG, Miller AK, Nasveld PE, Reid MG, Harris IE, Edstein MD. Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects. Antimicrob Agents Chemother. 2007;51:2709\u201315. https:\/\/doi.org\/10.1128\/AAC.01183-06.","journal-title":"Antimicrob Agents Chemother"},{"key":"7262_CR25","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50474","volume":"212","author":"RJ Commons","year":"2020","unstructured":"Commons RJ, McCarthy JS, Price RN. Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency. Med J Aust. 2020;212:152. https:\/\/doi.org\/10.5694\/mja2.50474.","journal-title":"Med J Aust"},{"key":"7262_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1710775","volume":"380","author":"MVG Lacerda","year":"2019","unstructured":"Lacerda MVG, Llanos-Cuentas A, Krudsood S, Lon C, Saunders DL, Mohammed R, et al. Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380:215\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1710775.","journal-title":"N Engl J Med"},{"key":"7262_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010458.pub3","author":"C Rodrigo","year":"2020","unstructured":"Rodrigo C, Rajapakse S, Fernando D. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. Cochrane Database Syst Rev. 2020. https:\/\/doi.org\/10.1002\/14651858.CD010458.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"7262_CR28","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1177\/030098589403100503","volume":"31","author":"SL Stockham","year":"1994","unstructured":"Stockham SL, Harvey JW, Kinden DA. Equine glucose-6-phosphate dehydrogenase deficiency. Vet Pathol. 1994;31:518\u201327. https:\/\/doi.org\/10.1177\/030098589403100503.","journal-title":"Vet Pathol"},{"key":"7262_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0166-6851(97)00150-3","volume":"90","author":"DP Knowles","year":"1997","unstructured":"Knowles DP, Kappmeyer LS, Perryman LE. Genetic and biochemical analysis of erythrocyte-stage surface antigens belonging to a family of highly conserved proteins of Babesia equi and Theileria species. Mol Biochem Parasitol. 1997;90:69\u201379. https:\/\/doi.org\/10.1016\/S0166-6851(97)00150-3.","journal-title":"Mol Biochem Parasitol"},{"key":"7262_CR30","doi-asserted-by":"publisher","unstructured":"Schwint ON, Knowles DP, Ueti MW, Kappmeyer LS, Scoles GA. Transmission of Babesia caballi by Dermacentor nitens (Acari: Ixodidae) Is restricted to one generation in the absence of alimentary reinfection on a susceptible equine host. J Med Entomol. 2008;45:1152\u20135. https:\/\/doi.org\/10.1093\/jmedent\/45.6.1152.","DOI":"10.1093\/jmedent\/45.6.1152"},{"key":"7262_CR31","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1128\/JCM.37.7.2285-2290.1999","volume":"37","author":"LS Kappmeyer","year":"1999","unstructured":"Kappmeyer LS, Perryman LE, Hines SA, Baszler TV, Katz JB, Hennager SG, et al. Detection of equine antibodies to Babesia caballi by recombinant B. caballi rhoptry-associated protein 1 in a competitive-inhibition enzyme-linked immunosorbent assay. J Clin Microbiol. 1999;37:2285\u201390. https:\/\/doi.org\/10.1128\/JCM.37.7.2285-2290.1999.","journal-title":"J Clin Microbiol"},{"key":"7262_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jep.2006.10.036","volume":"111","author":"BN Lenta","year":"2007","unstructured":"Lenta BN, Vonthron-S\u00e9n\u00e9cheau C, Soh RF, Tantangmo F, Ngouela S, Kaiser M, et al. In vitro antiprotozoal activities and cytotoxicity of some selected Cameroonian medicinal plants. J Ethnopharmacol. 2007;111:8\u201312. https:\/\/doi.org\/10.1016\/j.jep.2006.10.036.","journal-title":"J Ethnopharmacol"},{"key":"7262_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11239-0","volume":"10","author":"G Camarda","year":"2019","unstructured":"Camarda G, Jirawatcharadech P, Priestley RS, Saif A, March S, Wong MHL, et al. Antimalarial activity of primaquine operates via a two-step biochemical relay. Nat Commun. 2019;10:3226. https:\/\/doi.org\/10.1038\/s41467-019-11239-0.","journal-title":"Nat Commun"},{"key":"7262_CR34","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/oxfordjournals.jbchem.a121979","volume":"101","author":"M Tamura","year":"1987","unstructured":"Tamura M, Yubisui T, Takeshita M, Kawabata S, Miyata T, Iwanaga S. Structural comparison of bovine erythrocyte, brain, and liver NADH-Cytochrome b5 reductase by HPLC mapping1. J Biochem. 1987;101:1147\u201359. https:\/\/doi.org\/10.1093\/oxfordjournals.jbchem.a121979.","journal-title":"J Biochem"},{"key":"7262_CR35","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1128\/AAC.00777-06","volume":"50","author":"B Pradines","year":"2006","unstructured":"Pradines B, Mamfoumbi MM, Tall A, Sokhna C, Koeck J-L, Fusai T, et al. In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti. Antimicrob Agents Chemother. 2006;50:3225\u20136. https:\/\/doi.org\/10.1128\/AAC.00777-06.","journal-title":"Antimicrob Agents Chemother"},{"key":"7262_CR36","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1021\/acs.jcim.4c00049","volume":"64","author":"GA Landrum","year":"2024","unstructured":"Landrum GA, Riniker S. Combining IC50 or Ki values from different sources is a source of significant noise. J Chem Inf Model. 2024;64:1560\u20137. https:\/\/doi.org\/10.1021\/acs.jcim.4c00049.","journal-title":"J Chem Inf Model"},{"key":"7262_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jtbi.2017.07.017","volume":"430","author":"P Cao","year":"2017","unstructured":"Cao P, Klonis N, Zaloumis S, Khoury DS, Cromer D, Davenport MP, et al. A mechanistic model quantifies artemisinin-induced parasite growth retardation in blood-stage Plasmodium falciparum infection. J Theor Biol. 2017;430:117\u201327. https:\/\/doi.org\/10.1016\/j.jtbi.2017.07.017.","journal-title":"J Theor Biol"},{"key":"7262_CR38","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00549-7","volume":"23","author":"JH Proost","year":"2021","unstructured":"Proost JH, Eleveld DJ, Struys MMRF. Population pharmacodynamic modeling using the sigmoid emax model: influence of inter-individual variability on the steepness of the concentration\u2013effect relationship: a simulation study. AAPS J. 2021;23:10. https:\/\/doi.org\/10.1208\/s12248-020-00549-7.","journal-title":"AAPS J"},{"key":"7262_CR39","doi-asserted-by":"crossref","unstructured":"Wongsrichanalai C, Barcus MJ, Muth S, Sutamihardja A, Wernsdorfer WH. A review of malaria diagnostic tools: microscopy and rapid diagnostic test (RDT). 2007. www.malaria.mr4.org","DOI":"10.4269\/ajtmh.2007.77.119"},{"key":"7262_CR40","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ttbdis.2019.01.004","volume":"10","author":"C Maji","year":"2019","unstructured":"Maji C, Goel P, Suthar A, Mandal KD, Gopalakrishnan A, Kumar R, et al. Lumefantrine and o-choline\u2014parasite metabolism specific drug molecules inhibited in vitro growth of Theileria equi and Babesia caballi in MASP culture system. Ticks Tick-borne Dis. 2019;10:568\u201374. https:\/\/doi.org\/10.1016\/j.ttbdis.2019.01.004.","journal-title":"Ticks Tick-borne Dis"},{"key":"7262_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ph15081005","volume":"15","author":"SI Shah","year":"2022","unstructured":"Shah SI, Nasir F, Malik NS, Alamzeb M, Abbas M, Rehman IU, et al. Efficacy evaluation of 10-hydroxy chondrofoline and tafenoquine against Leishmania tropica (HTD7). Pharmaceuticals. 2022;15:1005. https:\/\/doi.org\/10.3390\/ph15081005.","journal-title":"Pharmaceuticals"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-026-07262-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-026-07262-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-026-07262-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T11:55:26Z","timestamp":1770033326000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13071-026-07262-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7262"],"URL":"https:\/\/doi.org\/10.1186\/s13071-026-07262-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7769436\/v1","asserted-by":"object"}]},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Blood from healthy, hemoparasite-free horses were used in this study to maintain in vitro cultures of\n                      T. equi\n                      and\n                      B. caballi\n                      . Blood collections were performed according to protocols approved by the Institutional Animal Care and Use Committees of the University of Idaho (protocol # 2024\u201326) and Washington State University (protocol # 6982).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. No personal data or images of individuals were included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}